Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics (2020)

First Author: Arshad U
Attributed to:  MICA: New combination therapy against MDR TB targeting the respiratory chain funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2020.04.16.20068379

Publication URI: http://dx.doi.org/10.1101/2020.04.16.20068379

Type: Preprint